Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647790 · ClinicalTrials.gov registry record
Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 79
- Enrollment target
NCT00647790: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00647790 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00647790 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to find a way to learn the hormone receptor status of a tumor before surgery is done. By testing for the hormone receptor proteins, doctors can find out if the breast cancer uses hormones to grow. This is important since the hormone receptor status of a tumor helps doctors decide if extra treatment like chemotherapy or pills are needed.
Interventions
- PROCEDURE PET scan with injection of 5-8 mCi of 18FES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2006-11 |
| Est. Completion | 2013-06 |
What the finished NCT00647790 record still lists
NCT00647790 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 79 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PET scan with injection of 5-8 mCi of 18FES is the first listed.
NCT00647790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00647790 about?
NCT00647790 is a clinical study titled "Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer". The purpose of this study is to find a way to learn the hormone receptor status of a tumor before surgery is done. By testing for the hormone receptor proteins, doctors can find out if the breast cancer uses hormones to grow. This is important since the hormone receptor status of a tumor helps docto...
What is the current status of trial NCT00647790?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2006-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00647790?
The interventions under investigation include: PET scan with injection of 5-8 mCi of 18FES (PROCEDURE).
Who is sponsoring clinical trial NCT00647790?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia